Journal
NEUROREPORT
Volume 27, Issue 4, Pages 235-241Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNR.0000000000000526
Keywords
Alzheimer disease transgenic mouse; blood-brain barrier; human umbilical cord blood-derived mesenchymal stem cell; intravenous
Categories
Funding
- Korean Health Technology R&D Project, the Ministry of Health and Welfare, Republic of Korea [HI12C1821, HI14C3484]
- Samsung Medical Center [GFO1150171]
Ask authors/readers for more resources
The aim of this study was to track the migration of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) administered through a single intravenous injection and to observe the consequential therapeutic effects in a transgenic Alzheimer's disease mouse model. Ten-month-old APP/PS1 mice received a total injection of 1x10(6)cells through the lateral tail vein and were killed 1, 4, and 7 days after administration. On the basis of immunohistochemical analysis, hUCB-MSCs were not detected in the brain at any of the time points. Instead, most of the injected mesenchymal stem cells were found to be distributed in the lung, heart, and liver. In terms of the molecular effects, statistically significant differences in the amyloid protein, neprilysin, and SOX2 levels were not observed among the groups. On the basis of the results from this study, we suggest that single intravenously administered hUCB-MSCs are not delivered to the brain and also do not have a significant influence on Alzheimer's disease pathology. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available